scholarly journals MARCKS protein overexpression in inflammatory breast cancer

Oncotarget ◽  
2016 ◽  
Vol 8 (4) ◽  
pp. 6246-6257 ◽  
Author(s):  
Maroua Manai ◽  
Jeanne Thomassin-Piana ◽  
Amor Gamoudi ◽  
Pascal Finetti ◽  
Marc Lopez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Protein Overexpression ◽  
Marcks Protein

MARCKS protein overexpression is associated with poor prognosis in male breast cancer

2019 ◽  
Vol 26 (4) ◽  
pp. 513-522
Author(s):  
Maroua Manai ◽  
Syrine Abdeljaoued ◽  
Aïda Goucha ◽  
Olfa Adouni ◽  
Ilhem Bettaieb ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Poor Prognosis ◽  
Male Breast ◽  
Protein Overexpression ◽  
Marcks Protein

Inflammatory Breast Cancer: Correlation between Clinical and Radiologic Findings

1997 ◽  
Vol 37 (4) ◽  
pp. 763
Author(s):  
Hye Won Lee ◽  
Jeong Mi Park ◽  
Sei Hyun Ahn ◽  
Gyungyup Gong
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Radiologic Findings

INFLAMMATORY BREAST CANCER FOLLOWED BY CONTRALATERAL BREAST METASTASIS WITH INFLAMMATORY CHANGE

1995 ◽  
Vol 45 (5) ◽  
pp. 413-418
Author(s):  
TATSUMASA ANDOH ◽  
YUICHI IINO ◽  
HIDETADA AOYAGI ◽  
NORITAKA SUGAMATA ◽  
HIROYUKI TAKEI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Contralateral Breast ◽  
Inflammatory Change ◽  
Breast Metastasis

scholarly journals Inflammatory Breast Cancer: Clinical Characteristics and Influence of Molecular Subtypes on Treatment Response

2021 ◽  
Vol 107 (1_suppl) ◽  
pp. 12-12
Author(s):  
D Aissaoui ◽  
M Bohli ◽  
R Ben Amor ◽  
J Yahyaoui ◽  
A Hamdoun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Response ◽  
Inflammatory Breast Cancer ◽  
Hormone Receptor ◽  
Triple Negative ◽  
Molecular Subtypes ◽  
Luminal A ◽  
Her2 Positive ◽  
Luminal B ◽  
Significant Difference

Introduction: Inflammatory Breast Cancer (IBC) is a rare and very aggressive breast cancer with poor prognosis. The prevalence is different from a country to another. In Tunisia, it is about 5 to 7% of breast cancer. The aim of this study is to describe the epidemiological and histopathological features of patients with inflammatory breast cancer and to evaluate the treatment response according to the molecular subtypes. Methods: This retrospective review identified 31 patients with no metastatic IBC treated in our radiotherapy department between December 2019 and November 2020. IBC was confirmed using the clinical criteria. Baseline clinic-pathological and treatment information was retrieved from medical records. Statistical analysis was performed with IBM SPSS V.20. Results: Median age was 51.3 years [27-68]. 48% of tumors were grade 3. The average tumor size was 36mm [10-90]. The histological type was ductal carcinoma in 97%. Vascular invasion was noted in 24 patients (77%). Thirty patients were classified as stage IIIB and one patient was IIIC. 74% were hormone receptor positive and 45% were HER2 positive. Luminal B was the predominant subtype (52%) followed by Her2 positive (32%), Luminal A (23%), and triple negative (3%) All patients had chemotherapy: neoadjuvant for 26 patients (84%) and adjuvant for 5 patients (16%). Nine patients (29%) had tumor pathological complete response (pCR). Partial response was observed in 18 patients (58%). Lymph node pCR was noted in 16% of cases (n=5). Endocrine therapy and trastuzumab were given to 76% and 45% of patients, respectively. The influence of the molecular subtype was not statistically significant on the response to neoadjuvant treatment. The highest rate of pCR were 43% for Her2positive, then 27%, 21% and 9% for Luminal B, Luminal A and Triple negative, respectively (p=0.2). Conclusion: Our study showed a high percentage of hormone receptor and Her2+ (74% and 45% respectively) in IBC. Luminal B was the most frequent subtype. Anthracycline-based chemotherapy and trastuzumab improved the pCR rate: 44% for Her2positive. Triple negative showed poorer pCR than other breast cancer subtype without a significant difference. A larger study is warranted to confirm our findings.

scholarly journals Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors

2021 ◽  
Vol 10 (1) ◽  
pp. 1929724
Author(s):  
François Bertucci ◽  
Laurys Boudin ◽  
Pascal Finetti ◽  
Christophe Van Berckelaer ◽  
Peter Van Dam ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors

scholarly journals Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature

2021 ◽  
pp. 1071-1079
Author(s):  
Jennifer Y. Ge ◽  
Beth Overmoyer
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Inflammatory Breast Cancer ◽  
Targeted Therapies ◽  
De Novo ◽  
Review Of The Literature ◽  
Her2 Positive ◽  
Rare Type ◽  
Favorable Prognosis ◽  
Poor Outcomes

Inflammatory breast cancer (IBC) is a rare type of breast cancer that is associated with poor outcomes compared with non-IBC. Overexpression of HER2 is enriched in IBC, and those with HER2-positive disease have a relatively favorable prognosis, with improved survival over the last two decades driven by the advent of novel targeted therapies. Here, we present two patients who have survived for over 10 years after being diagnosed with de novo metastatic HER2-positive IBC. We review the data for the treatments available for metastatic HER2-positive IBC and the evolving treatment recommendations for this disease.

scholarly journals Segmentation of HER2 protein overexpression in immunohistochemically stained breast cancer images using Support Vector Machines

2016 ◽  
Vol 762 ◽  
pp. 012050 ◽  
Author(s):  
Raquel Pezoa ◽  
Luis Salinas ◽  
Claudio Torres ◽  
Steffen Härtel ◽  
Cristián Maureira-Fredes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Support Vector Machines ◽  
Support Vector ◽  
Protein Overexpression ◽  
Her2 Protein ◽  
Vector Machines
Sign in / Sign up

Export Citation Format

Share Document